An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
Thomas Powles(Queen Mary University of London), Dónal Landers(Clinical Research Institute), Robert McEwen(AstraZeneca (United Kingdom)), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Petros Grivas(Seattle Cancer Care Alliance), Iwanka Kozarewa(AstraZeneca (United Kingdom)), Pablo Maroto(Hospital de Sant Pau), Frédéric Rolland(Institut de Cancérologie de l'Ouest), Alain Ravaud(Bordeaux Population Health), Florence Joly(Centre François Baclesse), Srikala S. Sridhar(Princess Margaret Cancer Centre), Danielle Carroll(AstraZeneca (United Kingdom)), Robert J. Jones(Beatson West of Scotland Cancer Centre), Daniel P. Petrylak(Yale University), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Natalie Cook(The Christie NHS Foundation Trust), Arjun Vasant Balar(NYU Langone Health), Jan Cosaert(AstraZeneca (United Kingdom)), Darren Hodgson(AstraZeneca (United Kingdom)), Florence Mercier(AstraZeneca (United Kingdom)), Simon Chowdhury(Sarah Cannon Research Institute), Aude Fléchon(Institut Català d'Ornitologia), Richard Mather(AstraZeneca (United Kingdom)), Joan Carles(Vall d'Hebron Hospital Universitari)
Cited by 115
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k